Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intelgenx Technologies Corp
(OP:
IGXT
)
N/A
UNCHANGED
Last Price
Updated: 3:57 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1670
Today's Range
N/A - N/A
52wk Range
0.1020 - 0.1990
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q1 2024
May 15, 2024
Intelgenx Technologies just reported results for the first quarter of 2024.
Via
InvestorPlace
IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023
March 21, 2024
Intelgenx Technologies just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Performance
More News
Read More
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Via
Benzinga
IntelGenx Q2 2023: Revenue Decline 67%, Operating Costs Rise, What About Net Loss?
August 14, 2023
Via
Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
Via
Benzinga
FDA Gives Nod To IntelGenx's Migraine Solution As Revenues Plunge 32%; Q1 Results Report
May 11, 2023
Via
Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
April 05, 2023
Via
Benzinga
IntelGenx's Q4 And Full-Year 2022 Financials, 'On The Cusp' Of Rapid Growth?
March 30, 2023
Via
Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 30, 2023
Via
Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
January 27, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
January 26, 2023
Via
Benzinga
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
January 25, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
January 24, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
January 19, 2023
Via
Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
January 16, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
January 13, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 12, 2023
Via
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
Via
Benzinga
IntelGenx Reports Q3 2022 Financial Results, Management Anticipates Psychedelics Trials In 2023
November 10, 2022
Via
Benzinga
New Oral Film Tech Improving Cannabinoid Onset Seeks Patent Protection
November 03, 2022
Via
Benzinga
Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track
October 25, 2022
Via
Benzinga
Short Volatility Alert: IntelGenx Technologies Corp.
October 04, 2022
Via
Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
August 01, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From July 29, 2022
July 29, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.